Nevertheless, ER−PR+ tumors have been traditionally considered for hormonal therapies and even included in the Luminal A group in the absence of ERBB2 amplification in surrogate tumor subtype classifications [10]. This evidence concerns the gene ERBB2 and neoplasm.